Abstract 1702
Background
This single-arm, non-interventional study ML28306 aimed at evaluating the effectiveness and safety of 1L Bevacizumab (BEV) treatment, focusing on 4 defined age groups, with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in routine practice.
Methods
The study is fully recruited with 1107 patients in 174 centers. 990 patients who received ≥1 BEV-dose to date are included in the present analysis. Enrollment started 02/2013; last patient out is expected 06/2017. Baseline characteristics, treatment regimen, effectiveness and safety data are documented for each patient. Primary endpoint is progression-free survival (PFS).
Results
In terms of age, 34% of patients were
Conclusions
Effectiveness and safety data of the 2. interim analysis is in line with results of the 1. analysis and other real-world data on BEV. The mPFS of the present study is comparable to the mPFS of 6.6m of the controlled E4599 trial, while the mOS is slightly lower (12.5m vs 14.2m). The safety profile is similar across age groups. No new safety signals were observed. Elderly patients seem to benefit in the same way as younger ones.
Clinical trial identification
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung ClinicalTrials.gov Identifier: NCT01827852
Legal entity responsible for the study
Roche Pharma AG
Funding
Roche Pharma AG
Disclosure
H.R. Wirtz: Membership on an advisory board or board of directors: MSD, Roche, Boehringer Ingelheim Corporate-sponsored research: TNI Medical. S. Lang, S. Hammerschmidt: Membership on an advisory board or board of directors: Roche. M. Reck: Membership on an advisory board or board of directors: Hoffmann-La Roche, Lilly, MSD, Astra Zeneca, BMS, Pfizer, Novartis, Celgene, Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract